| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1634/THEONCOLOGIST.2014-0465 |
| P8608 | Fatcat ID | release_rqzpcxiv3beevjrfokqq5k3tmi |
| P932 | PMC publication ID | 4571783 |
| P698 | PubMed publication ID | 26001391 |
| P5875 | ResearchGate publication ID | 277079311 |
| P50 | author | Alex A Adjei | Q107055463 |
| P2093 | author name string | Yujie Zhao | |
| P2860 | cites work | VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex | Q24293027 |
| VEGF-Trap: a VEGF blocker with potent antitumor effects | Q24535043 | ||
| Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Q24608039 | ||
| Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors | Q24676378 | ||
| Therapeutic options targeting angiogenesis in nonsmall cell lung cancer | Q26823727 | ||
| Vandetanib for the treatment of medullary thyroid cancer | Q26824828 | ||
| Lessons learned from the bevacizumab experience | Q26852509 | ||
| Anti-vascular endothelial growth factor therapy in breast cancer | Q26999473 | ||
| MET: a critical player in tumorigenesis and therapeutic target | Q27008925 | ||
| BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy | Q27650860 | ||
| FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer | Q27851554 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer | Q28251373 | ||
| R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways | Q28275289 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging | Q28293708 | ||
| Vascular endothelial growth factor is a secreted angiogenic mitogen | Q28646475 | ||
| Molecular mechanisms and clinical applications of angiogenesis | Q29547314 | ||
| Angiogenesis: an organizing principle for drug discovery? | Q29614538 | ||
| Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors | Q29615445 | ||
| Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial | Q29615711 | ||
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q29620127 | ||
| Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer | Q29622818 | ||
| Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). | Q30317994 | ||
| Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma | Q30472055 | ||
| AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. | Q30490422 | ||
| Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma | Q30661157 | ||
| New agents on the horizon in hepatocellular carcinoma | Q38074429 | ||
| Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy | Q38087230 | ||
| Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis | Q38115027 | ||
| Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer | Q38125964 | ||
| Understanding and targeting resistance to anti-angiogenic therapies | Q38133568 | ||
| Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'. | Q38153830 | ||
| Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use. | Q38166329 | ||
| Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. | Q38175454 | ||
| Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. | Q38189898 | ||
| RET revisited: expanding the oncogenic portfolio | Q38190360 | ||
| Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. | Q39120399 | ||
| Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model | Q39160279 | ||
| Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis | Q39186341 | ||
| Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance | Q39212474 | ||
| PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells | Q39433494 | ||
| Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo | Q39623814 | ||
| Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma | Q39681377 | ||
| Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. | Q40192837 | ||
| Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models | Q40198053 | ||
| Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma | Q40283618 | ||
| Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells | Q40959364 | ||
| Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study | Q43657215 | ||
| Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 | ||
| Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. | Q44304174 | ||
| Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms | Q44680981 | ||
| Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma | Q45143413 | ||
| Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. | Q46006772 | ||
| Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family | Q46135963 | ||
| E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition | Q46944486 | ||
| Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. | Q53545899 | ||
| Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. | Q54410290 | ||
| Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando | Q57579457 | ||
| Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II) | Q58023765 | ||
| The role of fibroblast growth factors in vascular development | Q78384186 | ||
| Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells | Q33386807 | ||
| A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer | Q33399785 | ||
| Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients | Q33588739 | ||
| (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor | Q33590458 | ||
| Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance | Q33627739 | ||
| Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure | Q33648995 | ||
| Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma | Q34038480 | ||
| Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. | Q34089525 | ||
| Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients | Q34114767 | ||
| Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors | Q34129930 | ||
| Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy | Q34157098 | ||
| Cabozantinib in progressive medullary thyroid cancer | Q34185084 | ||
| The discovery of placenta growth factor and its biological activity. | Q34245619 | ||
| Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch | Q34282342 | ||
| A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Q34322740 | ||
| PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis | Q34359534 | ||
| Targeting the PDGF signaling pathway in tumor treatment | Q34393461 | ||
| Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers | Q34626130 | ||
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Q34633525 | ||
| Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial | Q34638316 | ||
| Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen | Q34642136 | ||
| Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q34645665 | ||
| Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial | Q34650664 | ||
| Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial | Q34658812 | ||
| Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. | Q34662482 | ||
| Biomarkers for anti-angiogenic therapy in cancer. | Q34695003 | ||
| Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. | Q34728237 | ||
| Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast gro | Q34752683 | ||
| Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 | ||
| Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer | Q34806780 | ||
| Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase | Q34819659 | ||
| Adverse effects of anticancer agents that target the VEGF pathway | Q34990961 | ||
| Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation | Q35010176 | ||
| A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies | Q35011280 | ||
| The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer | Q35021680 | ||
| Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC | Q35050210 | ||
| Rapid vascular regrowth in tumors after reversal of VEGF inhibition | Q35052385 | ||
| Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models | Q35163538 | ||
| Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial | Q35195766 | ||
| The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis | Q35563524 | ||
| Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. | Q35623311 | ||
| Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis | Q35791487 | ||
| PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases | Q35811090 | ||
| Angiopoietins in tumours: the angiogenic switch | Q35861359 | ||
| Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. | Q35966757 | ||
| Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis | Q36111400 | ||
| Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis | Q36300824 | ||
| The VEGF pathway in cancer and disease: responses, resistance, and the path forward. | Q36526512 | ||
| Structure and physiology of the RET receptor tyrosine kinase | Q36555201 | ||
| Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer | Q36822111 | ||
| Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial | Q36910409 | ||
| The FGF family: biology, pathophysiology and therapy | Q36933339 | ||
| VEGF Trap induces antiglioma effect at different stages of disease | Q37284357 | ||
| ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside | Q37312735 | ||
| FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? | Q37333639 | ||
| Positive and negative modulation of angiogenesis by VEGFR1 ligands | Q37401612 | ||
| Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited | Q37403323 | ||
| Intricacies of bevacizumab-induced toxicities and their management | Q37406599 | ||
| Pathways mediating VEGF-independent tumor angiogenesis | Q37652164 | ||
| Lymphangiogenesis: Molecular mechanisms and future promise | Q37697245 | ||
| BIBF 1120 for the treatment of non-small cell lung cancer | Q37750755 | ||
| Targeting the ANGPT-TIE2 pathway in malignancy | Q37774852 | ||
| Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. | Q37827451 | ||
| Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword? | Q37970070 | ||
| Anti-angiogenesis therapy in cancer: current challenges and future perspectives | Q37994504 | ||
| Cediranib: a VEGF receptor tyrosine kinase inhibitor | Q38029363 | ||
| P433 | issue | 6 | |
| P921 | main subject | endothelium | Q111140 |
| P304 | page(s) | 660-673 | |
| P577 | publication date | 2015-05-22 | |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor | |
| P478 | volume | 20 |
| Q88771433 | 86/90Y-Based Theranostics Targeting Angiogenesis in a Murine Breast Cancer Model |
| Q33799297 | 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment in ApoE-/- mice |
| Q41367937 | A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma. |
| Q37189966 | Addressing the Symptoms or Fixing the Problem? Developing Countermeasures against Normal Tissue Radiation Injury. |
| Q92816090 | Advances of Zinc Signaling Studies in Prostate Cancer |
| Q90569887 | An Insight into the Angiogenic and Lymphatic Interplay in Pre-eclampsia Comorbid with HIV Infection |
| Q38631373 | An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. |
| Q37416749 | Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKT → NF-κB → CXCL5 signaling |
| Q39368829 | Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis. |
| Q96135356 | Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment |
| Q38763633 | Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches? |
| Q41258130 | Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review. |
| Q92764365 | Anti-angiogenic effects of the blue-green alga Arthrospira platensis on pancreatic cancer |
| Q91940207 | Anti-metastasis traditional Chinese medicine monomer screening system based on perinucleolar compartment analysis in hepatocellular carcinoma cells |
| Q38744423 | Antiangiogenic Effects of Nerve Growth Factor Loop 4 Monomeric Dipeptide Mimetic |
| Q36334914 | Antiangiogenic effects of oridonin |
| Q42366549 | Antitumor immunity induced by VE-cadherin modified DC vaccine |
| Q94545744 | Association of angiogenesis and inflammation-related gene functional polymorphisms with early-stage breast cancer prognosis |
| Q36958382 | BRAF kinase inhibitor exerts anti-tumor activity against breast cancer cells via inhibition of FGFR2. |
| Q92126848 | Biological Functions and Molecular Mechanisms of Antibiotic Tigecycline in the Treatment of Cancers |
| Q27853358 | Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies |
| Q58605561 | Body fatness, adipose tissue compartments and biomarkers of inflammation and angiogenesis in colorectal cancer: the ColoCare Study |
| Q36390700 | Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks |
| Q98163452 | Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment |
| Q90446036 | C-type lectin family XIV members and angiogenesis |
| Q47313921 | Cancer Hallmarks Analytics Tool (CHAT): a text mining approach to organize and evaluate scientific literature on cancer |
| Q39991182 | Cervical cancer systemic inflammation score: a novel predictor of prognosis |
| Q90571077 | Chemoresistance of Cancer Cells: Requirements of Tumor Microenvironment-mimicking In Vitro Models in Anti-Cancer Drug Development |
| Q47627726 | Clinical implications of in silico mathematical modeling for glioblastoma: a critical review. |
| Q90737495 | Clinical significance of a pvrl 4 encoded gene Nectin-4 in metastasis and angiogenesis for tumor relapse |
| Q92945264 | Combination of Epigallocatechin-3-gallate and Silibinin: A Novel Approach for Targeting Both Tumor and Endothelial Cells |
| Q64064784 | Coptidis Rhizoma: a comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology |
| Q94471894 | Correlation of gene polymorphisms of vascular endothelial growth factor with grade and prognosis of lung cancer |
| Q52661758 | Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma. |
| Q47176438 | Curcumin inhibits gastric cancer-derived mesenchymal stem cells mediated angiogenesis by regulating NF-κB/VEGF signaling |
| Q41103676 | Design, synthesis, and evaluation of VEGFR-targeted macromolecular MRI contrast agent based on biotin-avidin-specific binding |
| Q47597969 | Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments. |
| Q55031374 | Diminished oligomerization in the synthesis of new anti-angiogenic cyclic peptide using solution instead of solid-phase cyclization. |
| Q92863794 | Down-regulation of TGF-β, VEGF, and bFGF in vascular endothelial cells of chicken induced by a brittle star (Ophiocoma erinaceus) extract |
| Q37718673 | Dual roles of protein tyrosine phosphatase kappa in coordinating angiogenesis induced by pro-angiogenic factors. |
| Q38737411 | Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs |
| Q47105124 | Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis |
| Q45124523 | Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression |
| Q26771513 | Epidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis marker |
| Q37637658 | Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials |
| Q61798748 | Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics |
| Q90581934 | Extracellular Vesicles (EVs) from Lung Adenocarcinoma Cells Promote Human Umbilical Vein Endothelial Cell (HUVEC) Angiogenesis through Yes Kinase-associated Protein (YAP) Transport |
| Q44643445 | Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer |
| Q91796711 | Flaxseed Lignans as Important Dietary Polyphenols for Cancer Prevention and Treatment: Chemistry, Pharmacokinetics, and Molecular Targets |
| Q36772187 | Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway. |
| Q52668325 | How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive. |
| Q37731561 | Hsp90β promoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma |
| Q52665656 | Hypoxia-dependent mitochondrial fission regulates endothelial progenitor cell migration, invasion, and tube formation. |
| Q57041735 | Impaired tumor growth and angiogenesis in mice heterozygous for Vegfr2 (Flk1) |
| Q55019812 | In silico prediction of targets for anti-angiogenesis and their in vitro evaluation confirm the involvement of SOD3 in angiogenesis. |
| Q47118750 | Inhibition of STAT3/VEGF/CDK2 axis signaling is critically involved in the antiangiogenic and apoptotic effects of arsenic herbal mixture PROS in non-small lung cancer cells |
| Q91760986 | Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition |
| Q48330378 | Isolation and screening of proangiogenic and antiangiogenic metabolites producing rare actinobacteria from soil. |
| Q58698138 | It Takes Two: Endothelial-Perivascular Cell Cross-Talk in Vascular Development and Disease |
| Q38743870 | KIF26B, a novel oncogene, promotes proliferation and metastasis by activating the VEGF pathway in gastric cancer |
| Q26773408 | Killing cancer with platycodin D through multiple mechanisms |
| Q54977595 | Lymphatics-associated genes are downregulated at transcription level in non-small cell lung cancer. |
| Q28073613 | Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment |
| Q37745389 | MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2. |
| Q42654040 | MicroRNA-16-5p overexpression suppresses proliferation and invasion as well as triggers apoptosis by targeting VEGFA expression in breast carcinoma |
| Q99632062 | Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective |
| Q47998495 | Mouse models of neurodegenerative disease: preclinical imaging and neurovascular component. |
| Q47797389 | N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors |
| Q38772275 | Nanotherapy silencing the interleukin-8 gene produces regression of prostate cancer by inhibition of angiogenesis |
| Q57493127 | Netrin as a Novel Biomarker and Its Therapeutic Implications in Diabetes Mellitus and Diabetes-Associated Complications |
| Q47221234 | New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness |
| Q49800025 | New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications |
| Q86756703 | Nintedanib and ovarian cancer: standardise surgery in trials? |
| Q51824301 | Nintedanib in ovarian cancer. |
| Q42516349 | Nintedanib treatment delays prostate dorsolateral lobe cancer progression in the TRAMP model: Contribution to the epithelial-stromal interaction balance |
| Q37003836 | Peptide-coated gold nanoparticles for modulation of angiogenesis in vivo |
| Q41329829 | Pharmacokinetics of calycopterin and xanthmicrol, two polymethoxylated hydroxyflavones with anti-angiogenic activities from Dracocephalum kotschyi Bioss |
| Q38753875 | Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging Properties |
| Q50419857 | Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review. |
| Q47326758 | Potentiating angiogenesis arrest in vivo via laser irradiation of peptide functionalised gold nanoparticles. |
| Q92787614 | Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models |
| Q33897971 | Predictive model of thrombospondin-1 and vascular endothelial growth factor in breast tumor tissue |
| Q91584750 | Prognostic genes of melanoma identified by weighted gene co-expression network analysis and drug repositioning using a network-based method |
| Q45852322 | Prohibitin, relocated to the front ends, can control the migration directionality of colorectal cancer cells |
| Q38829362 | RNAi-mediated downregulation of oral cancer overexpressed 1 (ORAOV1) inhibits vascular endothelial cell proliferation, migration, invasion, and tube formation |
| Q64103672 | Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy |
| Q58607138 | Receptor Tyrosine Kinase-Targeted Cancer Therapy |
| Q90094407 | Reimaging biological barriers affecting distribution and extravasation of PEG/peptide- modified liposomes in xenograft SMMC7721 tumor |
| Q126338271 | Retracted Article: Panax notoginseng saponins regulate VEGF to suppress esophageal squamous cell carcinoma progression via DVL3-mediated Wnt/β-catenin signaling |
| Q33732986 | Revisiting the hallmarks of cancer |
| Q47150792 | Role of VEGFA gene polymorphisms in colorectal cancer patients who treated with bevacizumab |
| Q57169852 | Role of hypoxia-induced exosomes in tumor biology |
| Q52675438 | Role of the Nervous System in Tumor Angiogenesis. |
| Q49866596 | Roles of toll-like receptors: From inflammation to lung cancer progression |
| Q50107409 | SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models |
| Q58750993 | SOX5 induces lung adenocarcinoma angiogenesis by inducing the expression of VEGF through STAT3 signaling |
| Q26801785 | Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes |
| Q38767147 | Short peptides interfering with signaling pathways as new therapeutic tools for cancer treatment |
| Q89881990 | Silencing of HOXB9 suppresses cellular proliferation, angiogenesis, migration and invasion of prostate cancer cells |
| Q99614305 | Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study |
| Q57055294 | Targeted and Immune-based Therapies for Hepatocellular Carcinoma |
| Q45874034 | Targeted delivery of miR-199a-3p using self-assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma |
| Q26801841 | The Contribution of Angiogenesis to the Process of Metastasis |
| Q64962531 | The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study. |
| Q50864970 | The Precision of Hepatic Arterial Infusion Scintigraphy as a Quantitative Biomarker of Tumor Microvasculature. |
| Q39120772 | The Role of PDGFs and PDGFRs in Colorectal Cancer. |
| Q47553825 | The Role of Wnt Signalling in Angiogenesis |
| Q91742138 | The Role of YAP and TAZ in Angiogenesis and Vascular Mimicry |
| Q55437410 | The coordinated effects of Apatinib and Tripterine on the proliferation, invasiveness and apoptosis of human hepatoma Hep3B cells. |
| Q61803634 | The effect of cycling hypoxia on MCF-7 cancer stem cells and the impact of their microenvironment on angiogenesis using human umbilical vein endothelial cells (HUVECs) as a model |
| Q55518573 | The β3-integrin endothelial adhesome regulates microtubule-dependent cell migration. |
| Q64055886 | Tumor Neovascularization and Developments in Therapeutics |
| Q39393740 | Tumor angiogenesis revisited: Regulators and clinical implications. |
| Q64913955 | Ultrasonic Cavitation Ameliorates Antitumor Efficacy of Residual Cancer After Incomplete Radiofrequency Ablation in Rabbit VX2 Liver Tumor Model. |
| Q28073155 | Unraveling the Anticancer Effect of Curcumin and Resveratrol |
| Q47918409 | VEGF as a potential target in lung cancer |
| Q92012918 | Vascular PPARβ/δ Promotes Tumor Angiogenesis and Progression |
| Q52655088 | Vialinin A, an Edible Mushroom-Derived p-Terphenyl Antioxidant, Prevents VEGF-Induced Neovascularization In Vitro and In Vivo. |
| Q92308319 | Yu Ping Feng San Exert Anti-Angiogenesis Effects through the Inhibition of TSLP-STAT3 Signaling Pathways in Hepatocellular Carcinoma |
| Q35996844 | α-Mangostin, a Natural Agent, Enhances the Response of NRAS Mutant Melanoma to Retinoic Acid |
Search more.